Astellas New Data on XOSPATA in Acute Myeloid Leukemia at Hematology Meet

Emerging mutations in patients with treatment resistance, from Phase 3 ADMIRAL study, will be focus of oral presentation

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced the presentation of new data in acute myeloid leukemia (AML) at the 61^st American Society of Hematology (ASH) Annual Meeting, taking place Dec. 7-10 in Orlando, Fla.

Seven abstracts sponsored by Astellas focus on patients with relapsed (disease that has returned) or refractory (resistant to treatment) AML with a FLT3 mutation (FLT3mut+). The abstracts include new findings from the Phase 3 ADMIRAL trial – an oral presentation on emerging mutations in patients who develop resistance after an initial response to XOSPATA and two poster presentations focused on patient-reported outcomes – as well as data on cost-effectiveness, FLT3 testing and treatment patterns, and venetoclax combination therapy.

https://www.biospace.com/article/releases/astellas-presents-new-data-on-xospata-gilteritinib-in-flt3-mutation-positive-relapsed-refractory-acute-myeloid-leukemia-at-the-2019-american-society-of-hematology-annual-meeting/